GHRP-6 (10mg)

Description

What is GHRP‑6?

GHRP‑6 is the prototypical synthetic growth‑hormone‑releasing peptide, originally developed by Cyril Bowers in the 1980s. As a ghrelin‑receptor agonist it produces pulsatile GH release and a noticeable increase in hunger signaling—making it useful in appetite‑and‑GH preclinical models but also giving it a less selective profile than ipamorelin.

Mechanism of Action

• Ghrelin‑receptor (GHS‑R1a) agonist at pituitary somatotrophs and hypothalamic arcuate neurons
• Stimulates GH pulses independently of GHRH; synergizes with GHRH for supra‑additive GH release
• Activates NPY/AgRP neurons, producing a robust orexigenic effect
• Modest dose‑dependent elevation of prolactin and ACTH/cortisol reported at higher doses

Compound Properties

• Molecular formula: C₄₆H₅₆N₁₂O₆
• Molecular weight: ~872.45 g/mol
• CAS: 87616‑84‑0
• Sequence: His‑D‑Trp‑Ala‑Trp‑D‑Phe‑Lys‑NH₂
• Form: Lyophilized powder
• Unit size: 10 mg / vial
• Source: Solid‑phase peptide synthesis; ≥99% purity by HPLC

Research‑Reference Dosing

Published research‑reference ranges in clinical and preclinical literature:

• Bowers et al., Endocrinology (1984, 1991): foundational characterization in humans and animal models.
• Massoud et al., Clinical Endocrinology (1996): GH response to GHRP‑6 in GHD and normal adults.
• Laferrère et al., JCEM (2005): appetite and GH data following GHRP‑6 administration.

Research Findings

• Reliable pulsatile GH release via ghrelin‑receptor signaling (Bowers 1991)
• Robust increase in subjective hunger and food intake (Laferrère 2005)
• Strong GHRH synergy in paired‑peptide models

Known Side Effects Reported in Research/Trials

• Marked increase in appetite (primary class effect)
• Flushing, headache, injection‑site irritation
• Mild transient prolactin and cortisol elevation at higher doses
• Occasional reports of transient water retention and tingling

Storage & Handling

• Lyophilized (unreconstituted) vials: store at −20°C long‑term; short‑term 2–8°C acceptable.
• After reconstitution with bacteriostatic or sterile water: store at 2–8°C; use within 14–28 days per standard peptide stability guidance.
• Protect from light, heat, and repeated freeze‑thaw cycles. Handle in a sterile laboratory environment.

Certificate of Analysis

A Certificate of Analysis (COA) confirming identity and purity by HPLC / MS is available upon request. Contact Lonestar Peptides for lot‑specific documentation.

Summaries reference peer‑reviewed preclinical and clinical literature available as of early 2025. Newer findings may not be reflected. Researchers should consult current literature and conduct their own due diligence. Lonestar Peptides makes no claim of therapeutic benefit.